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Serum chitotriosidase and YKL-40 in acute pancreatitis: Reliability as prognostic marker
for disease severity and correlation with inflammatory markers
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Background/aim: Chitotriosidase and YKL-40, also called chitinase 3-like protein 1, are homologs of family 18 glycosyl hydrolases,
secreted by human macrophages and granulocytes under inflammatory conditions. Although increased levels of chitotriosidase and
YKL-40 are linked with several inflammatory diseases, the physiological utility of these two enzymes is still not fully characterized. This
study aims to analyse the serum YKL-40 and chitotriosidase levels of acute pancreatitis patients to assess whether their activity correlates
with acute pancreatitis and its severity.
Materials and methods: Chitotriosidase and YKL-40 levels, along with routine laboratory parameters, were determined from the serum
samples of 41 acute pancreatitis patients, at both onset and remission (male/female: 22/19), and 39 healthy subjects (male/female:
19/20). The Modified Glasgow Prognostic Score was used to predict the severity of the disease, and a correlation analysis was performed
between study variables.
Results: A statistically significant increase in both chitotriosidase and YKL-40 levels was observed in acute pancreatitis patients
compared to healthy controls (P < 0.001). Higher levels of YKL-40, chitotriosidase and C-reactive protein were found in patients with
acute pancreatitis at onset than in remission. The correlation analysis showed a statistically significant association between YKL-40
and chitotriosidase (p = 0.039, r = 0.323). The cut-off point for YKL-40, for detecting acute pancreatitis, was 60.3 with a sensitivity and
specificity of 84.9% and 84.6% (AUC: 0.890). The optimum cut-off points for chitotriosidase, for detecting acute pancreatitis, was 33.5
with a sensitivity and specificity of 79.5% and 78.4% (AUC: 0.899).
Conclusion: Elevated YKL-40 and chitotriosidase levels in acute pancreatitis patients demonstrate the importance of possible
macrophage involvement in the pancreatic microenvironment during acute pancreatitis progression.
Key words: Acute pancreatitis, YKL-40, chitotriosidase, inflammation

1. Introduction
Acute pancreatitis (AP) is a serious but reversible
inflammatory process of the pancreatic tissue that can
progress to systemic inflammatory response syndrome with
considerable morbidity and mortality in approximately
one-fifth of patients [1]. A sudden onset of abdominal
pain in conjunction with a rise of pancreatic enzymes that
are released from the acinar cells of the pancreas are the
basis for an AP diagnosis. Both amylase and lipase can be
elevated in distinct disease conditions, including perforated
gastric or duodenal ulcers, renal insufficiency, intestinal
obstruction, tubo-ovarian disease, and mesenteric
infarction [2]. Although less widely available in clinical
conditions, more specific rapid supplemental diagnostic

tests, such as urinary trypsinogen-2 and trypsinogen
activation peptide, do exist [3,4]. Due to the potential
for catastrophic deterioration, it is crucial to achieve
diagnostic stratification of injury severity and diagnostic
accuracy by the adjunctive use of additional diagnostic
assays. In this context, multiple risk stratification scores,
with different clinical and biochemical variables, are
proposed to determine the severity of AP. These scores
include the Ranson criteria, APACHE II score, SOFA, and
modified Glasgow Prognostic score (mGPS) [5]. However,
these systems are sometimes criticized as unnecessarily
complex, requiring multiple measurements and difficult to
perform for patients outside the intensive care unit due to
too many parameters they use.
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Chitin is a long-chain polysaccharide, which is the
major constituent of bacteria cell walls, the sheaths of
parasitic nematodes and fungi [6]. In mammals, despite
lacking endogenous chitin, several chitinase-like proteins
have been determined, though their function is not fully
understood [7]. Humans and mice express two active
chitinases, namely chitotriosidase (CHIT1) and acidic
mammalian chitinase (AMCAse), and at least three
chitinase-like proteins (CLPs), namely YKL-40 (chitinase
3-like protein 1), YKL-39 (chitinase 3-like protein 2) and
oviductin [8].
Chitotriosidase is a part of the chitinase enzyme family
and participates in the degradation of chitin and chitinlike substrates because of hydrolyses of N-acetyl-betaglucosaminide(1–4)-beta linkages. With this functional
property, chitotriosidase exerts antibacterial, fungicidal
and parasiticidal effects and participates in immune
defence. Chitotriosidase does so by involving macrophage
plasticity,
presenting
nonchitin
antigen-derived
peptides and effecting the straight stimulation of many
inflammatory cytokines, for instance interleukin-8 (IL-8)
and tumour growth factor-beta (TGF-β) [9]. Although no
chitotriosidase activity has been reported in the human
metabolism, chitotriosidase has been proposed to play a
key function in innate immunity and is considered a useful
marker of macrophage activation [10].
YKL-40 is a 40 kDa heparin- and chitin-binding
glycoprotein, which is secreted by various cells, including
vascular smooth muscle cells and macrophages. As a
novel inflammatory marker, YKL-40 has been found to be
elevated in several inflammatory and neoplastic disease
conditions, including atherosclerosis, benign prostatic
hyperplasia, diabetes mellitus, osteoarthritis (OA),
polymyositis, psoriasis, rheumatoid arthritis, cervical
cancer, and primary prostate cancer [11–18]. Although
Johansen et al. [19] found elevated serum YKL-40 levels in
AP patients, they failed to explore the relationship between
chitotriosidase and conventional markers of inflammation.
Based on the emerging roles of YKL-40 and
chitotriosidase in diseases characterized by inflammation
and fibrosis, we designed this study to explore the possible
role of YKL-40 and chitotriosidase in AP and to determine
whether these two parameters could be related to the
disease activity. Meanwhile, we also compared the clinical
significance of YKL-40 and chitotriosidase with systemic
markers of inflammation.
2. Materials and methods
2.1. Study participants
This prospective study comprised 41 patients with biliary
AP who were admitted to Çanakkale Onsekiz Mart
University (COMU) Hospital between September 2019 and
December 2020. The patients were followed during their

hospitalization period, and the mean hospitalization time
was 4.1 ± 3.2 days. AP diagnosis was established according
to the presence of severe abdominal pain, vomiting and
elevated serum amylase/lipase concentration (more than
three times the upper normal limit) or characteristic
radiological imaging, compatible with AP based on the
Atlanta classification [20]. The clinical follow-up of each
patient was performed prospectively until each patient
was discharged from hospital. Remission was defined
as symptom disappearance, normal pancreatic enzyme
levels and starting oral nutrition. Exclusion criteria was
defined as the existence of acute or chronic inflammatory
disorders, peripheral vascular disease, tumoral conditions,
renal and hepatic diseases, objective evidence, or prior
diagnosis of chronic pancreatitis, or use of nonsteroidal
antiinflammatory and anticoagulant drugs. Healthy
controls were chosen from the university and hospital staff.
All healthy controls were selected by an internal medicine
specialist and presented no complaints, symptoms, or
history of any tumoral, renal, hepatic, metabolic, or
endocrinologic disease conditions.
This study was performed in accordance with the
Declaration of Helsinki and approved by the COMU
Institutional Ethics Board (Approval date: 11.12.2019; No:
20-05). Prior to study enrolment, signed informed consent
was obtained from all the study participants.
2.2. Clinical and laboratory assessment
For each patient, the following clinical, laboratory and
demographic data were recorded: age, sex, aetiology of
AP (estimated by clinical history, physical examination,
routine blood tests and radiologic evaluations) and disease
severity (determined by a modified Glasgow prognostic
score (mGPS) within 48 h of admission). Eight parameters
of mGPS were evaluated, and the patients were graded as
mild (score < 3) or severe (score ≥ 3) according to the total
sum of the scores [21].
Routine complete blood count and biochemical
parameters, including amylase, lipase, alanine
aminotransferase, aspartate aminotransferase, albumin,
calcium, glucose, lactate dehydrogenase, blood urea
nitrogen, creatinine, erythrocyte sedimentation rate and
C-reactive protein (CRP) were determined. Fasting blood
samples were collected, at both the onset and remission
of the disease, from the antecubital vein after overnight
fasting without using any anticoagulant. Blood samples
were left on the clot, and serum was separated from cellular
elements by centrifugation (3000 rounds per minute for 15
min) within 2 h after blood sampling. All serum samples
were stored at –80 °C until the analysis was performed.
2.3. YKL-40 and chitotriosidase assay
Serum YKL-40 levels were measured by a double antibody
enzyme-linked immunosorbent assay (ELISA) kit, from
Sunred Biotechnology Company, made in Shanghai,
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China, Catalogue Number 201-12-2144. Chitotriosidase
concentrations were determined using commercially
available ELISA kits (Sunred, Shanghai, China), Catalogue
Number 201-12-3460.
2.4. Statistical analysis
All statistical analysis was performed using the SPSS
statistical program for Windows (IBM SPSS Statistics,
Version 20.0. Armonk, NY: IBM Corp). Continuous
and categorical variables were presented as median
interquartile range or mean ± standard deviation and n
(%), respectively. The chi-square test was used to determine
significant relationship between categorical variables. The
Shapiro–Wilk test was used to determine whether study
parameters had normal distribution in study groups, and
the Mann–Whitney test or Student’s t-test was used to
calculate the significance of the differences between the
two groups. For multiple comparisons one-way ANOVA
test, followed by Bonferroni post hoc test was performed
and adjusted p values were calculated. The Spearman
correlation analysis was used to identify the correlation
between YKL-40 and chitotriosidase, with other markers
of inflammation. Odds ratios (95% confidence intervals)
of the independent clinical and laboratory parameters
were calculated with univariate logistic regression model
to predict AP. Receiver operating characteristic (ROC)
curve analysis was used to identify optimal cut-off values of
YKL-40, chitotriosidase and other inflammation markers
with highest sensitivity and specificity for detection of AP
severity.
3. Results
Forty-one patients with biliary AP and 39 healthy subjects
were included in the present study. Twenty-two (53.6%) of
the patients with AP and 19 (48.7%) of the healthy subjects
were male. The median ages of the AP and control patients

were 69 (37–89) years and 64 (23–88) years, respectively.
No significant differences were observed in respect to the
ages and genders of the study groups. The mean serum
YKL-40 levels in the AP patients were 180.49 ± 62.01 ng/
mL and was found to be significantly elevated (p < 0.001)
compared with the level in the control group (36.12 ±
14.14). The mean serum chitotriosidase levels in the AP
patients was 58.44 ± 24.43 ng/mL and was significantly
elevated (p < 0.001) compared with the level in the healthy
controls (21.48 ± 11.81). Figure 1 shows the mean YKL-40
(Figure 1A) and chitotriosidase (Figure 1B) levels of the AP
patients at the onset and remission of AP compared with
those of the healthy controls. The clinical characteristics
and laboratory values, including conventional markers of
inflammation, of the study groups are given in Table 1.
The comparison of serum YKL-40 and chitotriosidase
levels and other systemic inflammation markers at onset
and remission are shown in Table 2. Higher YKL-40,
chitotriosidase, white blood cell (WBC), erythrocyte
sedimentation rate and CRP were demonstrated in the
AP patients at the onset of the disease compared with the
remission. A correlation analysis revealed a significant
correlation between YKL-40 and chitotriosidase (r =
0.323, p = 0.039) (Figure 2A). Although a significant
correlation was found between CRP and YKL-40 (r =
0.591, p < 0.001) (Figure 2B), no significant correlation
was observed between CRP and chitotriosidase (r = 0.172,
p = 0.282). Table 3 summarizes the correlation analysis of
study variables in AP patients at the onset of the disease.
In order to predict AP, we also created a univariable
logistic regression model to study the associations
between AP and independent inflammatory markers
including YKL-40 and chitotriosidase (Table 4). We
found a significant improvement in performance using
conventional inflammatory markers as well as YKL-40

Figure 1. YKL-40 (A) and chitotriosidase (B) levels of the acute pancreatitis patients at onset and remission in comparison with healthy
controls.
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Table 1. Demographic and laboratory data of the patients with acute pancreatitis and healthy controls.
Acute pancreatitis
(n = 41)

Control group
(n = 39)

t, z, or
Chi-square

p

Age (years)

69 (37–90)

64 (23–80)

–1.050a

0.201

Gender (F/M)

19/22

20/19

0.195

0.823

WBC (/mm3 × 103)

12.80 ± 6.23

7.37 ± 2.79

5.071c

< 0.001

Hemoglobin (g/dL)

12.9 ± 2.22

12.62 ± 1.95

0.732

0.467

Platelet (/mm × 10 )

257.49 ± 83.09

245.26 ± 113.33

0.552

0.582

NLR

12.05 ± 2.07

2.77 ± 1.73

3.564c

<0.001

PLR

268.02 ± 191.64

139.25 ± 62.85

4.435

<0.001

CRP (mg/L)

12.19 ± 13.19

0.72 ± 0.95

5.552c

< 0.001

Sedimentation (mm/h)

37.00 ± 25.45

19.62 ± 12.45

3.750

< 0.001

YKL-40 (ng/mL)

180.49 ± 62.01

36.12 ± 14.14

14.514c

< 0.001

Chitotriosidase (ng/mL)

58.44 ± 24.43

21.48 ± 11.81

8.678

< 0.001

3

3

b

c
c

c

c

c

a: nonparametric test; b: chi-square test; c: independent sample t-test;
WBC: White blood cell, NLR: Neutrophil-lymphocyte ratio, PLR: Platelet-lymphocyte ratio, CRP: C-reactive protein.
Table 2. Comparison of serum YKL-40 and chitotriosidase levels and other markers of inflammation at onset and
remission of acute pancreatitis patients (n = 41).
Onset

Remission

t-value

p

12.80 ± 6.23

6.98 ± 2.20

5.641

<0.001

Platelet (/mm ×10 )

257.49 ± 83.09

267.98 ± 116.75

–0.469

0.882

NLR

12.05 ± 2.07

3.48 ± 1.74

3.480

<0.001

PLR

268.02 ± 191.64

201.56 ± 132.77

0.967

0.044

Sedimentation (mm/h)

37.00 ± 25.45

20.68 ± 12.88

3.508

0.005

CRP (mg/dL)

12.19 ± 13.19

1.20 ± 1.01

5.320

<0.001

YKL-40 (ng/mL)

180.49 ± 62.01

85.50 ± 32.78

8.671

<0.001

Chitotriosidase (ng/mL)

58.44 ± 24.43

34.49 ± 17.71

5.082

<0.001

WBC (/mm3×103)
3

3

WBC: White blood cell, NLR: Neutrophil-lymphocyte ratio, PLR: Platelet-lymphocyte ratio, CRP: C-reactive
protein.

and chitotriosidase according to univariable regression
analysis. Multivariable analysis was not performed because
of the relatively low number of cases.
The severity of AP was calculated according to the
mGPS. According to this scoring system, 22 patients
(53.7%) were classiﬁed as having mild AP, and 19 patients
(46.3%) were classiﬁed as having severe AP. According to
the disease severity, Table 5 provides the comparison of
YKL-40 and chitotriosidase with other study variables at
the onset of the disease.
The Receiver Operating Characteristic (ROC) curve
analysis suggested that the optimum YKL-40 level cutoff points for determining AP was ≥60.3 ng/mL with a
sensitivity, specificity, negative predictive value (NPV) and

positive predictive value (PPV) of 84.9%, 84.6%, 78.9% and
82.6, respectively (AUC: 0.890). Optimum chitotriosidase
level cut-off points for determining AP was ≥33.5 ng/
mL with a sensitivity, specificity, NPV and PPV of 79.5%,
78.4%, 79.3% and 78.6, respectively (AUC: 0.899) (Table 6).
YKL-40 and chitotriosidase failed to demonstrate a certain
cut-off value, with adequate sensitivity and specificity, for
differentiating mild AP patients from severe AP patients
(Table 6).
4. Discussion
This study has shown that YKL-40 and chitotriosidase
levels are elevated in patients with AP in comparison to
in healthy controls. Both enzyme levels were found to
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Figure 2. Comparison of YKL-40 with chitotriosidase (A) and C reactive protein (CRP) (B)
Table 3. Correlation analysis of study variables at onset of acute pancreatitis.
Chitotriosidase

YKL-40

Sedimentation

CRP

r

p

r

WBC

0.106

0.509

CRP

0.172

Sedimentation

–0.109

YKL-40
Chitotriosidase

WBC

p

r

p

r

p

r

p

–0.244

0.123

0.316

0.057

–0.341

0.029

-

-

0.282

0.591

<0.001

0.055

0.746

-

-

-

-

0.520

–0.258

0.124

-

-

-

-

-

-

0.323

0.039

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

WBC: White blood cell, CRP: C-reactive protein.
Table 4. Univariable logistic regression analysis to determine
acute pancreatitis in patients that admitted to emergency
department.
Univariable analysis
p value

OR

(95% C.I.)

Age

0.201

1.020

0.989–1.053

Sex

0.659

1.219

0.507–2.933

WBC

<0.001

1.482

1.219–1.802

CRP

<0.001

3.340

1.823–6.119

Sedimentation

0.001

1.050

1.019–1.081

YKL-40

0.011

1.163

1.036–1.308

Chitotriosidase

<0.001

1.120

1.065–1.178

be decreased after treatment. Interestingly, the YKL40 and chitotriosidase activity was not affected by the
initial severity of the disease, suggesting that some factor
or factors common to all stages of the disease, apart
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from inflammation, may play a significant role in the
course of the disease. Furthermore, serum YKL-40 and
chitotriosidase levels were found to have high sensitivity,
specificity, and predictive values in patients with AP.
Based on the data we provided, it can be suggested that
both YKL-40 and chitotriosidase may be regarded as
valuable biomarkers of inflammation in AP patients. Thus,
our ﬁndings add new and relevant proof to the growing
body of literature on the role of chitinases and chitin-like
proteins in the physiopathology of AP.
As the incidence of AP is increasing, it is imperative to
determine the severity of the disease to recognize patients
that are at risk of developing highly unfavourable outcomes.
To achieve these goals, the determination of inflammatory
activity has considerable prognostic relevance. Apart
from clinical assessments, biochemical and radiological
evaluations are commonly used to determine the presence
and the severity of pancreatic inflammation [2,22].
Unfortunately, determining AP severity in the early
phases of the disease is still challenging and depends
chiefly on analyzing different clinical and biochemical

ÜNAL ÇETİN et al. / Turk J Med Sci
Table 5. Comparison of YKL-40 and chitotriosidase with other study variables at onset of acute pancreatitis (AP)
according to disease severity measured by modified Glasgow Prognostic score.
Mild AP

Severe AP

t-value

p

WBC (/mm ×10 )

13.20 ± 7.57

12.34 ± 4.36

0.432

0.865

Platelet (/mm3×103)

247.95 ± 84.82

268.52 ± 81.91

0.787

0.456

NLR

11.28 ± 10.51

12.95 ± 11.10

0.658

0.583

PLR

241.16 ± 186.64

299.14 ± 197.67

0.786

0.360

Sedimentation(mm/h)

27.63 ± 19.03

46.88 ± 28.05

–2.455

0.023

CRP (mg/dL)

7.83 ± 8.76

17.24 ± 15.72

–2.410

0.038

YKL-40 (ng/mL)

186.32 ± 58.39

173.72 ± 66.95

–0.553

0.676

Chitotriosidase (ng/mL)

60.98 ± 26.55

55.48 ± 22.05

0.724

0.464

3

3

WBC: White blood cell, NLR: Neutrophil-lymphocyte ratio, PLR: Platelet-lymphocyte ratio, CRP: C-reactive
protein.
Table 6. Overall accuracy and ROC analyses of YKL-40 and chitotriosidase with other conventional inﬂammation markers
to determine acute pancreatitis and differentiate mild cases from severe cases according to the modified Glasgow Prognostic
score.
Acute pancreatitis
vs. controls

AUC

Cut-Off

Sensitivity
(%)

Specificity
(%)

PPV
(%)

NPV
(%)

WBC

0.827

8.45

79.5

81.1

80.8

79.8

NLR

0.874

4.1

89.2

81.4

80.5

89.7

PLR

0.785

170.0

73.8

73.7

75.6

71.8

Platelet

0.563

236.5

56.4

56.8

56.6

56.6

CRP

0.959

1.46

89.7

89.2

89.3

89.6

Sedimentation

0.699

20.0

69.2

70.3

70.0

69.5

YKL-40

0.890

60.3

84.9

84.6

82.6

78.9

Chitotriosidase

0.899

33.5

79.5

78.4

78.6

79.3

Specificity
(%)

PPV
(%)

NPV
(%)

Mild vs severe
acute pancreatitis

AUC

Cut-Off

Sensitivity
(%)

WBC

0.545

8.85

54.1

55.0

54.6

54.5

NLR

0.602

7.1

57.9

50.0

50.0

57.9

PLR

0.626

202.0

63.2

50.0

52.2

61.1

Platelet

0.571

244

54.1

55.0

54.6

54.5

CRP

0.570

2.05

51.4

52.5

52.0

51.9

Sedimentation

0.692

23.5

62.2

65.0

64.0

63.2

YKL-40

0.580

107.77

59.5

57.5

58.3

58.7

Chitotriosidase

0.474

42.03

48.6

47.5

48.1

48.0

WBC: White blood cell, NLR: Neutrophil-lymphocyte ratio, PLR: Platelet-lymphocyte ratio, CRP: C-reactive protein.

variables. Therefore, there is an eager demand for a simple
and inexpensive method that can precisely evaluate the
presence and the severity of AP. In this context, there are
several biochemical assays that are being used routinely
or on an as-needed basis in AP diagnosis. However, to
the best of our knowledge, no previous studies have

been undertaken to simultaneously evaluate YKL-40 and
chitotriosidase in the peripheral blood of patients with AP.
Chitotriosidase belongs to a family of various chitinase
and chitinase-like proteins and is involved in defence
against chitin-containing pathogens [23]. Chitotriosidase
is mainly produced by activated macrophages and
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granulocytes under inflammatory conditions. As is well
known, macrophages in the pancreas and other associated
organs are mostly activated in AP and, furthermore, secrete
inflammatory cytokines and mediators, which determine
the severity of pancreatitis [24]. However, elevated
chitotriosidase secretion in acute and chronic inflammatory
disease conditions, including lysosomal storage diseases,
sarcoidosis, interstitial lung disease, tuberculosis, acute
malaria (induced by Plasmodium falciparum) and
granulomatous diseases have been reported; to the best
of our knowledge, this is the first study showing the role
of chitotriosidase in AP patients [10,25–27]. The results
of the present study have demonstrated elevated levels
of chitotriosidase in AP patients, suggesting a prompt
activation of pancreatic macrophages in the disease course
regardless of the disease severity.
This study revealed increased YKL-40 levels in AP
patients irrespective of disease severity, as reflected by
mGPS. YKL-40 and chitotriosidase belong to the same
family, “mammalian chitinase-like proteins,” but YKL-40
is not a chitinase; rather, it binds tightly to chitin particles
[28]. YKL-40 is a potential serum biomarker of distinct
benign and malignant disease states, including diabetes
mellitus, coronary artery disease, systemic sclerosis,
psoriasis, dementia, benign prostatic hyperplasia, cervical
cancer, and primary prostate cancer [14–17, 28, 29].
Unfortunately, there is scarce evidence for an association
between YKL-40 and AP. In this context, the Johansen et
al.’s [19] study is the first and only study in the literature that
demonstrates the role of YKL-40 in patients with AP. The
authors not only reported elevated serum YKL-40 levels in
AP patients at admission but also much higher serum YKL40 levels in patients with severe disease than mild disease.
Apart from AP, the association between YKL-40 and
pancreatic cancer has recently been demonstrated in a large
series of patients with unresectable pancreatic cancer [30].
Serum YKL-40, IL6, and CRP were found to be elevated
in advanced-stage cancer patients with poor performance
statuses. Moreover, combined elevations of YKL-40, serum
IL6, and CRP were reported to be associated with worse
survival rates in contrast to isolated, high concentrations
in a single marker. Although we have demonstrated a
significant increase in YKL-40 levels in AP patients, we
did not observe a significant difference regarding disease
severity in respect to YKL-40 levels in AP patients. Based
on these data, we suggest that YKL-40 plays a pivotal role
in AP, irrespective of the severity of the disease, possibly by
regulating key pathways and processes within the respective
pancreatic microenvironment during AP. These processes
include inﬂammation, angiogenesis, cell proliferation,
differentiation, and remodelling of the extracellular matrix.
Although there is no ideal single serum marker for
predicting the presence and the severity of AP, CRP is a
practical marker of inflammation and necrosis, with a
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specificity and sensitivity of 80%. However, CRP must be
measured more than 48 h after the beginning of clinical
symptoms because the peak CRP level appears 24 to 48 ho
after the onset of pancreatitis [2, 31, 32]. Regarded as an
acute phase reactant, circulating YKL-40 may provide novel
information regarding the severity of inflammatory disease,
as has already been demonstrated by multiple studies [33,
34]. In patients with endotoxemia, which is followed by
increased plasma IL-6 and TNF-alpha levels, plasma YKL40 increased earlier than serum CRP, which is a nonspeciﬁc
acute-phase protein synthesized in the liver in response to
stimulation, mainly from IL6 [19, 35]. YKL-40 is secreted
rapidly by activated monocytes and neutrophils because
of ongoing inflammatory response, and this premature
elevation of YKL-40 from the CRP makes it a suitable
candidate for AP diagnosis [19, 36]. This study has revealed
a positive correlation between serum CRP and YKL-40
levels, but no association was found between CRP and
chitotriosidase levels. Similarly, Johansen et al. [19] found a
positive correlation between serum YKL-40 and CRP levels
at admission and after 48 h (admission: r = 0.70; 48 h: r =
0.66) (p <0.0001).
The primary limitation of this study is the relatively
small sample size used for the analyses. Additionally, based
on the acute inflammatory nature of AP, it would have
enhanced our study if we had simultaneously measured
other well-known inflammatory factors that play vital
roles in the pathological process of AP, such as IL-6, IL-8,
TNF-alpha. Yet another limitation of this study was that the
duration of patient follow-up was very short, and it would
have been beneficial to monitor the changes in YKL-40 and
chitotriosidase over a longer period.
5. Conclusion
Despite the above-mentioned limitations of the current
study, we have demonstrated for the first time that YKL40 and chitotriosidase are simple, reliable, and inexpensive
potential biomarkers of AP, with high specificity and
sensitivity rates. Moreover, we propose that elevated
serum YKL-40 and chitotriosidase activity in patients
with AP suggests the importance of possible macrophage
involvement in the pancreatic microenvironment during
AP progression. Both assays may be combined with other
markers of inflammation to detect the presence and severity
of the disease and to fortify the efficacy of the treatment.
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